Theriva Biologics, Inc. 8-K

What Happened
Theriva Biologics, Inc. (TOVX) announced on Feb 18, 2026 that it entered into an exclusive worldwide license agreement with Rasayana Therapeutics, Inc. The deal grants Rasayana the exclusive right (with sublicensing ability) to research, develop, manufacture and commercialize products covered by Theriva’s licensed IP, including SYN-020, an oral recombinant intestinal alkaline phosphatase. Rasayana will assume responsibility and all costs for development and commercialization.

Key Details

• Upfront payment: $300,000 received by Theriva on Feb 18, 2026.
• Milestones: up to $16,000,000 in development milestones and up to $22,000,000 in sales milestones (aggregate potential $38,000,000).
• Royalties and sublicenses: Theriva entitled to tiered royalties in the low to mid single digits on net product sales and a share of any sublicense revenue.
• Termination/controls: Rasayana may terminate for any or no reason with 90 days’ notice; Theriva can terminate if Rasayana suspends material development for 180 days or fails to use commercially reasonable efforts to meet milestones. On termination, rights revert to Theriva.

Also disclosed: Theriva issued a press release on Feb 17, 2026 announcing the agreement.

Why It Matters
This agreement shifts development and commercialization costs and clinical risk for SYN-020 from Theriva to Rasayana, while providing Theriva with immediate cash ($300K) and potential future upside through milestone payments, royalties and sublicense revenue (total milestone potential $38M plus royalties). For investors, the deal reduces Theriva’s near-term cash burden and creates contingent value tied to Rasayana’s development and commercial success — but the agreement also allows Rasayana broad discretion (including a 90-day termination right), which adds execution risk to Theriva’s future revenues.